Erythropoietin in cardiovascular diseases.

Renoprotective potential of exogen erythropoietin on experimental ruptured abdominal aortic aneurysm model: An animal study

Objective(s): The aim of this study is to investigate the renoprotective effect of erythropoietin (EPO) on hypovolemic shock and ischemia/reperfusion (IR) injury on kidneys as end-organs in an experimentally-created ruptured abdominal aortic aneurysm (rAAA) model.Materials and Methods: Thirty anesthetized Sprague-Dawley male rats were ra...

The Frequency of Resistance to Synthetic Erythropoietin and Its Risk Factors among Chronic Hemodialysis Patients in Kerman

Background: The aim of this study was to determine the frequency of resistance to synthetic erythropoietin and factors affecting it among chronic hemodialysis patients in Kerman/ Iran. Methods: This cross- sectional study was performed on chronic hemodialysis patients of three hemodialysis centers in Kerman, Iran during 3 successive months in the summer of 201...

Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study.

BACKGROUND Studies suggest that in patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF and mortality. Trials of erythropoietin-stimulating agents in persons with kidney disease have also suggested an increased incidence of adverse clinical events. No large studies of which we are aware have evaluated the association of endogenous erythropoietin le...

University of Groningen Anemia and erythropoietin in cardiovascular disease

Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

Background. Cardiovascular morbidity and mortality are very high in patients with chronic kidney disease (CKD). The purpose of this study is to evaluate the impact of continuous erythropoietin receptor activator (CERA) on selected biomarkers of cardiovascular disease, left ventricle structure, and function in CKD. Material and Methods. Peripheral blood was collected from 25 CKD patients before ...

Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.

Erythropoietin is a hypoxia-induced hormone that is a major regulator of normal erythropoiesis. Over the last decade, the production of recombinant human erythropoietin has revolutionized the treatment of anemia associated with chronic renal failure, and has led to a greater understanding of anemia pathophysiology and to the elucidation of the interactions of erythropoietin, iron, and erythropo...